CClinicalTrials.gg
Sign In
Status unknownNCT03507816Updated Apr 30, 2019

A Multidrug-resistant (MDR) and Extensively Drug- Resistant (XDR) Tuberculosis Study in Alsace

An observational study in Tuberculosis, sponsored by University Hospital, Strasbourg, France. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-30.

Sponsored by University Hospital, Strasbourg, France · Observational

The sponsor has not verified this record recently (last verified Apr 2019), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
22
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to examine the epidemiology of TB MR in Strasbourg and evaluate the second-line anti-tuberculosis treatments effectiveness, and the relevance and adequacy of the treatments with WHO recommendations. During years 2006-2016, all new cases of MDR TB or XDR TB diagnosed Strasbourg University Hospital will be included in the study (22 cases). Data were collected from the Center for Tuberculosis Control (CLAT) records, the patient's medical records.

02

Conditions studied

  • Tuberculosis

Browse trials for

Keywords

  • Tuberculosis
  • Multi-drug Resistant Tuberculosis
  • Observational retrospective study
  • Clinical epidemiology
  • Treatment outcome
  • Migrant
  • Precarity
03

In context

Tuberculosis

1,417 studies on the registry are indexed under Tuberculosis; 208 are open to participants now.

This study's planned enrollment of 22 is below the median of 250 across 421 observational studies indexed under Tuberculosis.

Browse Tuberculosis studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with proven MDR or XDR tuberculosis

Inclusion criteria

  • Major patient (≥18 years old)
  • Patient hospitalized at Strasbourg University Hospital from 2006 to 2016, with proven MDR or XDR tuberculosis

Exclusion criteria

Exclusion Criteria:

  • Refusal of the patient to participate in the study
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
22 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Study of clinical characteristics of patients hospitalized at Strasbourg University Hospital from 2006 to 2016, with proven MDR or XDR tuberculosis

    Time frame: The period from January 1st, 2006 to December 31st, 2016 will be examined

07

Study locations

1 of 1 sites recruiting
  • Service de Maladies Infectieuses et Tropicales
    Strasbourg, 67091, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03507816
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Apr 25, 2018
Start date
Feb 23, 2018
Primary completion
Feb 2020 (estimated)
Completion
Feb 2020 (estimated)
Last update
Apr 30, 2019

Study contacts

Xavier ARGEMI, MD
Contact
xavier.argemi@chru-strasbourg.fr
33 3 69 55 11 87
Magalie Paz, MD
Contact
magalie.paz@chru-strasbourg.fr
33 3 69 55 11 87
Xavier ARGEMI, MD
study director · University Hospital, Strasbourg, France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Tuberculosis→

Other studies from this sponsor

University Hospital, Strasbourg, France

Start the discussion